ClinicalTrials.gg

Program

BGM0504

Also written as “BGM0504 tablets”, “BGM0504 Administered SC” and “BGM0504 Injection single-dose pen”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Overweight, led by BrightGene Bio-Medical Technology.

Furthest: phase 3, since Nov 7, 202416 company-led studies, 3 open or runningNext primary completion: Feb 28, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BrightGene Bio-Medical Technology163 open or runningphase 3since Nov 7, 2024Nov 7, 2024Feb 28, 2027phase 2 · NCT07658560

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Nov 7, 2024.

  1. Mar 27, 2025Phase 1 study in OverweightNCT06920056 · 28 enrolled · China
  2. Apr 3, 2025Phase 2 study in ObesityNCT06911203 · 96 enrolled · China
  3. Apr 8, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT06929156 · 34 enrolled · China
  4. May 14, 20252 phase 2 studiesNCT06974825, NCT06973681
  5. Jul 11, 2025Phase 3 study in Diabetes Mellitus, Type 2NCT07064486 · 152 enrolled · Indonesia
  6. Sep 3, 2025Phase 1 study in ObesityNCT07166081 · 80 enrolled · United States
  7. Nov 13, 2025Phase 1 study in ObesityNCT07239973 · 75 enrolled · China
  8. Jan 26, 2026Phase 1 study in OverweightNCT07382908 · 144 enrolled · China
  9. Apr 22, 2026Phase 1 study in Chinese Healthy VolunteersNCT07566572 · 144 enrolled · China
  10. Jun 11, 2026Phase 2 study in OverweightNCT07658560 · 200 planned · China
  11. Jul 24, 2026Phase 3 study in Diabetes Mellitus, Type 2NCT07743983 · 372 planned · China
  12. Oct 13, 2026Primary completion moved from 2026-07-31 to 2027-04-30Date moved laterphase 3 · +9 months · NCT07064486
  13. Oct 15, 2026Primary completion moved from 2025-12-29 to 2026-11-14Date moved laterphase 3 · +11 months · NCT06716203
  14. Oct 15, 2026Primary completion moved from 2026-03-20 to 2026-11-14Date moved laterphase 3 · +8 months · NCT06716216

Ahead

  1. Feb 28, 2027Primary completion: phase 2 study in OverweightNCT07658560
  2. Apr 30, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07064486
  3. Sep 30, 2028Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07743983

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07743983Diabetes Mellitus, Type 2 · China3RecruitingSep 30, 2028372
NCT07658560Overweight · China2RecruitingFeb 28, 2027200
NCT07566572Chinese Healthy Volunteers · China1CompletedAug 31, 2026144
NCT07382908Overweight · China1CompletedApr 9, 2026144
NCT07239973Obesity · China1CompletedMar 5, 202675
NCT07166081Obesity · United States1CompletedMar 16, 202680
NCT07064486Diabetes Mellitus, Type 2 · Indonesia3Active, not recruitingApr 30, 2027152
NCT06974825Diabetes Mellitus, Type 2 · China2CompletedAug 13, 202467
NCT06973681Overweight · China2CompletedSep 13, 2024120
NCT06929156Diabetes Mellitus, Type 2 · China1CompletedDec 25, 202534
NCT06911203Obesity · China2CompletedJan 14, 202696
NCT06920056Overweight · China1CompletedJul 25, 202528
NCT06716216Diabetes Mellitus, Type 2 · China3CompletedAug 25, 2026553
NCT06716203Diabetes Mellitus, Type 2 · China3CompletedAug 13, 2026227
NCT06714955Obesity · United States1CompletedJan 21, 202530
NCT06704581Overweight · China3CompletedMar 17, 2026652

How it is read

Names in the registry

  • “BGM0504”, 16 entries
  • “BGM0504 tablets”, 6 entries
  • “BGM0504 Administered SC”, 3 entries
  • “BGM0504 Injection single-dose pen”, 2 entries
  • “Drug: 5 mg BGM0504 Administered SC”, 1 entry

Codes read as this program: BGM0504.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.